Key facts
- Synteny’s last known valuation is $11.5M (Oct 2023).
- It has raised $2.2M; the latest was Later Stage VC in Jan 2026.
- Notable investors include Alumni Ventures, In-Q-Tel, Picus Capital, Hawktail, Imperial Enterprise Lab — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Synteny
- ·The full record, as it builds
Funding rounds
No funding rounds for Synteny are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Synteny
Developer of a bioinformatics tool designed to decode the signal of immune repertoires to power disease discoveries. The company's tool leverages high-throughput data analysis, generative modeling, and precision immunology techniques to interpret immune repertoires, enabling biotechnology researchers and pharmaceutical developers to identify therapeutic targets, accelerate drug development, and advance personalized medicine through deeper information into immune dynamics.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2021
- Employees
- 16
- Website
- synteny.ai/
- Ownership
- Privately Held (backing)
Synteny doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Synteny shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Synteny in its N-PORT filings yet. We sweep new filings monthly.